Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733592 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL13610814 | 0.85 | ALDH1A1 (0.56) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL8630154 | 0.85 | HPGD (0.56) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL6964815 | 0.83 | ALDH1A1 (0.54) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL10104553 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL10888489 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL7195729 | 0.79 | CES1 (0.54) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL1553692 | 0.79 | HPGD (0.61) | ALDH1A1SMN1; SMN2MAPK1HPGDLMNA | |
| SCHEMBL7495655 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 | |
| SCHEMBL7495651 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2MAPK1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914250-B | Novel process for synthesizing tilobaxib | 珂思玛股份公司 | 2023-06-27 | — | — | CN | claimed |
| EP-3609877-B1 | PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S P A (IT) | 2020-12-23 | — | — | EP | claimed |
| US-10807962-B2 | Process for the synthesis of firocoxib | COSMA S.P.A. (IT) | 2020-10-20 | — | — | US | claimed |
| US-20200102279-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S.P.A. (IT) | 2020-04-02 | — | — | US | claimed |
| CN-110914250-A | Novel process for synthesizing felicoxib | 珂思玛股份公司 | 2020-03-24 | — | — | CN | claimed |
| EP-3609877-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | Cosma S.p.A. (IT) | 2020-02-19 | — | — | EP | claimed |
| WO-2018188763-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S.P.A. (IT) | 2018-10-18 | — | — | WO | claimed |
| CN-110914250-B | Novel process for synthesizing tilobaxib | 珂思玛股份公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110105314-B | Method for preparing feloxicib | 江苏君若药业有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-3609877-B1 | PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S P A (IT) | 2020-12-23 | — | — | EP | disclosed |
| EP-3609877-B1 | PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S P A (IT) | 2020-12-23 | — | — | EP | disclosed |
| US-10807962-B2 | Process for the synthesis of firocoxib | COSMA S.P.A. (IT) | 2020-10-20 | — | — | US | disclosed |
| US-10807962-B2 | Process for the synthesis of firocoxib | COSMA S.P.A. (IT) | 2020-10-20 | — | — | US | disclosed |
| US-20120190846-A1 | MICHAEL ADDITION REACTION PRODUCT AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | DIC CORPORATION. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190846-A1 | MICHAEL ADDITION REACTION PRODUCT AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | DIC CORPORATION. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190846-A1 | MICHAEL ADDITION REACTION PRODUCT AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | DIC CORPORATION. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2450344-A1 | MICHAEL ADDITION REACTION PRODUCT AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | DIC Corporation (JP) | 2012-05-09 | — | — | EP | disclosed |
| WO-2012000846-A1 | METAL FREE BLEACHING COMPOSITION | BASF SE (DE) | 2012-01-05 | — | — | WO | disclosed |
| US-6022906-A | α-aminoacetophenone photoinitiators | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-02-08 | — | — | US | disclosed |
| US-4582862-A | QUICK-SETTING PRINTING INKS BASED ON ACRYLATED RESINS | CIBA-GEIGY CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102279-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | PPOX, RIOX2, CYP4X1 | ALDH1A1 458/4885TSHR 4101/4885SMN1; SMN2 3962/4885 |
| US-20120190846-A1 | MICHAEL ADDITION REACTION PRODUCT AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | PARP14, TIPARP, PARP16 | ALDH1A1 590/4885TSHR 4224/4885SMN1; SMN2 4455/4885 |
| US-10807962-B2 | Process for the synthesis of firocoxib | RIOX2, PPOX, CYP4X1 | ALDH1A1 437/4885TSHR 3783/4885SMN1; SMN2 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.